AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock

AstraZeneca plc and Merck & Co., Inc.’s Lynparza (olaparib) has reinforced is lead among PARP inhibitors for prostate cancer with the publication of data from the Phase III PROpel trial showing the drug, combined with Johnson & Johnson’s Zytiga (abiraterone) and prednisone, resulted in lower risk of disease progression or death in first-line patients, irrespective of homologous recombination repair (HRR) mutation status.

Consequently, Lynparza stands to potentially gain access to a significantly larger share of the prostate cancer market, given both the first-line setting as well as efficacy in both HRR-mutated and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

02 Jun 2025

• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

02 Jun 2025

• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.